Operative therapy of benign prostatic hyperplasia: Enucleation procedures (HoLEP and ThuVEP) [Operative Therapie der benignen Prostatahyperplasie: Enukleierende Verfahren (HoLEP und ThuVEP)]

被引:0
|
作者
Bach T. [1 ]
Bschleipfer T. [2 ]
Muschter R. [3 ]
机构
[1] Urologischen Zentrums Harburg, Minimal-Invasive Urologie und Lasertherapie, Asklepios Klinik Harburg Eißendorfer, Pferdeweg 52
[2] Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen, Justus-Liebig-Universität Gießen, Gießen
[3] Klinik für Urologie und Kinderurologie, Diakoniekrankenhaus Rotenburg (Wümme), Rotenburg (Wümme)
来源
Der Urologe | 2013年 / 52卷 / 3期
关键词
Adenoma enucleation; Adenoma; prostatic obstructive; Laser enucleation; Laser surgery; Prostatic syndrome; benign;
D O I
10.1007/s00120-013-3114-8
中图分类号
学科分类号
摘要
Open simple prostatectomy is not only the oldest but also the most effective treatment option for benign prostatic obstruction. Laser enucleation has been established as a transurethral minimally invasive alternative especially but not exclusively for large volume prostates. To date two laser systems, holmium:YAG laser enucleation of the prostate (HoLEP) and thulium:YAG laser vapoenucleation of the prostate (ThuVEP) have been established. Both treatment modalities have similarities in terms of wavelength and surgical technique but differ in the type of energy released (pulsed versus continuous wave). The HoLEP and ThuVEP procedures lead to a significant improvement in symptoms, quality of life, urinary flow and post-void residual urine. Surgery-related morbidity, especially bleeding complications is significantly reduced with laser enucleation. For HoLEP the durability of the results was shown for a follow-up interval of up to 10 years while for ThuVEP the follow-up interval reached 18 months due to the shorter time since clinical implementation of this method. © 2013 Springer-Verlag Berlin Heidelberg.
引用
收藏
页码:345 / 349
页数:4
相关论文
共 18 条
  • [11] Interessenkonflikte bei wissenschaftlichen Publikationen und mögliche KonsequenzenEine kritische Analyse am Beispiel der benignen Prostatahyperplasie (BPH)Conflicts of interest in scientific publications and possible consequencesA critical analysis using the example of benign prostatic hyperplasia (BPH)
    Jonas Herrmann
    Christopher Netsch
    Die Urologie, 2025, 64 (4) : 352 - 357
  • [12] S2e-Leitlinie der Deutschen UrologenKonservative und medikamentöse Therapie des benignen ProstatasyndromsS2e guideline of the German urologistsConservative and pharmacologic treatment of benign prostatic hyperplasia
    K. Höfner
    T. Bach
    R. Berges
    K. Dreikorn
    C. Gratzke
    S. Madersbacher
    M.-S. Michel
    R. Muschter
    M. Oelke
    O. Reich
    C. Tschuschke
    T. Bschleipfer
    Der Urologe, 2016, 55 : 184 - 194
  • [13] EN-BLOC HOLEP VS EN-BLOC GREENLEP: COMPARING INTRA AND POST-OPERATIVE OUTCOMES FOR EN-BLOC ENUCLEATION TECHNIQUE USING TWO KINDS OF LASER TO TREAT PATIENTS AFFECTED BY BENIGN PROSTATIC ENLARGEMENT (BPE)
    Rodriguez Socarras, Moises Elias
    Saitta, Giuseppe
    Cuadros, Vanesa
    Elbers Javier, Reinoso
    Rijo, Enrique
    Michel Mercado, Ivan
    Fernandez del Alamo, Julio
    Gomez Rivas, Juan
    Llanes, Luis
    Juarez del Dago, Pablo
    Gomez Sancha, Fernando
    JOURNAL OF UROLOGY, 2020, 203 : E485 - E486
  • [14] En-Bloc MoLEP (Moses Laser Enucleation of Prostate) vs. En-Bloc HoLEP: Comparing intra and post-operative outcomes for En-Bloc enucleation technique with early apical release, to treat patients affected by Benign Prostatic Enlargement (BPE)
    Rodriguez Socarras, M. E.
    Fernandez Del Alamo, J.
    Gomez Rivas, J.
    Llanes Gonzalez, L.
    Carrion, D.
    Reinoso Elbers, J.
    Cuadros Rivera, V.
    Juarez Del Dago, P.
    Garcia Cruz, E.
    Gomez Sancha, F.
    EUROPEAN UROLOGY, 2021, 79 : S93 - S94
  • [15] Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate: A new potential target for medical therapy of benign prostatic hyperplasia [Expression des "corticotropin releasing faktor rezeptors 2" (CRFR2) in der humanen Prostata: Ein möglicher ansatzpunkt bei der therapie der benignen prostatahyperplasie]
    Tezval H.
    Merseburger A.S.
    Seidler M.
    Serth J.
    Kuczyk M.A.
    Oelke M.
    Der Urologe, 2008, 47 (9): : 1079 - 1084
  • [16] EN-BLOC ENUCLEATION TECHNIQUE USING MOSES LASER (EN-BLOC MOLEP) VS EN-BLOC HOLEP: COMPARING INTRA AND POST-OPERATIVE OUTCOMES FOR EN-BLOC ENUCLEATION TECHNIQUE WITH EARLY APICAL RELEASE, TO TREAT PATIENTS AFFECTED BY BENIGN PROSTATIC ENLARGEMENT (BPE)
    Rodriguez Socarras, Moises
    Fernandez Del Alamo, Julio
    Esposito, Fabio
    Reinoso Elbers, Javier
    Gomez Rivas, Juan
    Carrion, Diego
    Cuadros Rivera, Vanesa
    Llanes Gonzalez, Luis
    Juarez del Dago, Pablo
    Gomez Sancha, Fernando
    JOURNAL OF UROLOGY, 2021, 206 : E165 - E165
  • [17] Die operative Therapie des benignen Prostatasyndroms in DeutschlandEine Darstellung der Versorgungssituation auf Basis der Qualitätsberichte von 2006 bis 2019Contemporary surgical management of benign prostatic obstruction in GermanyA population-wide study based on German hospital quality report data from 2006 to 2019
    Annemarie Uhlig
    Martin Baunacke
    Christer Groeben
    Angelika Borkowetz
    Björn Volkmer
    Sascha A. Ahyai
    Lutz Trojan
    Nicole Eisenmenger
    Andreas Schneider
    Christian Thomas
    Johannes Huber
    Marianne Leitsmann
    Der Urologe, 2022, 61 (5): : 508 - 517
  • [18] Patient’s behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by “Prostate and Expectations of Treatment Epidemiology Research (PETER) study group”Miktionsbeschwerden und Therapieerwartungen von Patienten mit benigner Prostatahyperplasie unter medikamentöser Therapie mit Risiko einer klinischen Progression: eine prospektive Studie der „Prostate and Expectations of Treatment Epidemiology Research“ (PETER) Gruppe
    Peter Weibl
    Tobias Klatte
    Peter Laurinc
    Roman Tomaškin
    Shahrokh F. Shariat
    Miroslav Helbich
    Danica Fackovcova
    Peter Bujdák
    Wiener klinische Wochenschrift, 2015, 127 : 363 - 368